OPT התחייבויות חוב מצטברות Opthea

Opthea Limited (OPT) is developing innovative therapies for diabetic retinopathy, leveraging low demand elasticity and strong pricing power. Drug delivery relies on strict climate control to preserve medicinal properties. However, the costs of final trials in the absence of sales are creating a cash gap, with the indicator standing at 0.00. This chart illustrates the market's valuation dynamics for the asset.

Total debt measures the volume of external liabilities, determining a business's financial autonomy and its readiness to scale through leverage. For Opthea Limited, amid regulatory barriers and raw material supply chain risks, the total debt figure serves as an indicator of resilience to clinical trial disruptions, confirming the company's fundamental ability to fund development without critical dependence on creditors.